StemCell Therapy

Moderna Inc (MRNA) is near the top in its industry group according to InvestorsObserver. MRNA gets an overall rating of 64. That means it scores higher than 64 percent of stocks. Moderna Inc gets a 74 rank in the Biotechnology industry. Biotechnology is number 11 out of 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 64 means the stock is more attractive than 64 percent of stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Moderna Inc (MRNA) stock is higher by 9.39% while the S&P 500 has fallen -10.28% as of 9:49 AM on Monday, Mar 16. MRNA has risen $2.00 from the previous closing price of $21.30 on volume of 1,125,105 shares. Over the past year the S&P 500 is down -14.14% while MRNA has risen 5.05%. MRNA lost -$1.55 per share the over the last 12 months.

To see the top 5 stocks in Biotechnology click here.

Go here to read the rest:
Is Moderna Inc (MRNA) Stock Near the Top or Bottom of the Biotechnology Industry? - InvestorsObserver

This entry was posted on March 16, 2020 at 1:46 pm and is filed under Biotechnology. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |